XML 53 R42.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

OPERATING SEGMENTS (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
OPERATING SEGMENTS |
Schedule of financial information for each of the entity's reportable segments, including the impact of the preceding changes on previously reported full year 2021 net sales and operating income | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, 2023
​ |  | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
​ | ​ | 2023 Reported | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Fixed | ​ | ​ | ​ | 2023 Reported
​ | ​ | Valued at 2023 |  | ​ | ​ |  | Currency | ​ |  | Valued at 2024
(millions) | ​ | Management Rates |  | Other | ​ |  | Rate Change | ​ |  | Management Rates
Net Sales | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ |  | ​ | ​
Global Industrial | ​ | ​ | $7,193.1 | ​ | ​ | ​ | $407.3 | ​ | ​ | ​ | ​ | $40.1 | ​ | ​ | ​ | ​ | $7,640.5
Global Institutional & Specialty | ​ | ​ | 4,994.0 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 20.6 | ​ | ​ | ​ | ​ | 5,014.6
Global Healthcare & Life Sciences | ​ | ​ | 1,576.9 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 30.6 | ​ | ​ | ​ | ​ | 1,607.5
Global Pest Elimination | ​ | ​ | - | ​ | ​ | ​ | 1,061.5 | ​ | ​ | ​ | ​ | 8.7 | ​ | ​ | ​ | ​ | 1,070.2
Other | ​ | ​ | 1,442.3 | ​ | ​ | ​ | (1,442.3) | ​ | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | -
Corporate | ​ | ​ | 69.1 | ​ | ​ | ​ | (26.5) | ​ | ​ | ​ | ​ | 0.1 | ​ | ​ | ​ | ​ | 42.7
Subtotal at fixed currency rates | ​ | ​ | 15,275.4 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 100.1 | ​ | ​ | ​ | ​ | 15,375.5
Effect of foreign currency translation | ​ | ​ | 44.8 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (100.1) | ​ | ​ | ​ | ​ | (55.3)
Consolidated reported GAAP net sales | ​ | ​ | $15,320.2 | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $15,320.2
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating Income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Global Industrial | ​ | ​ | $1,080.7 | ​ | ​ | ​ | $39.0 | ​ | ​ | ​ | ​ | $2.3 | ​ | ​ | ​ | ​ | $1,122.0
Global Institutional & Specialty | ​ | ​ | 823.0 | ​ | ​ | ​ | 14.9 | ​ | ​ | ​ | ​ | 3.9 | ​ | ​ | ​ | ​ | 841.8
Global Healthcare & Life Sciences | ​ | ​ | 160.0 | ​ | ​ | ​ | (6.7) | ​ | ​ | ​ | ​ | 7.5 | ​ | ​ | ​ | ​ | 160.8
Global Pest Elimination | ​ | ​ | - | ​ | ​ | ​ | 209.0 | ​ | ​ | ​ | ​ | 1.4 | ​ | ​ | ​ | ​ | 210.4
Other | ​ | ​ | 255.0 | ​ | ​ | ​ | (255.0) | ​ | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | -
Corporate | ​ | ​ | (331.7) | ​ | ​ | ​ | (1.2) | ​ | ​ | ​ | ​ | 0.1 | ​ | ​ | ​ | ​ | (332.8)
Subtotal at fixed currency rates | ​ | ​ | 1,987.0 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | 15.2 | ​ | ​ | ​ | ​ | 2,002.2
Effect of foreign currency translation | ​ | ​ | 5.3 | ​ | ​ | ​ | - | ​ | ​ | ​ | ​ | (15.2) | ​ | ​ | ​ | ​ | (9.9)
Consolidated reported GAAP operating income | ​ | ​ | $1,992.3 | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $- | ​ | ​ | ​ | ​ | $1,992.3
Schedule of financial information for each of the entity's reportable segments | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Second Quarter Ended | ​ | Six Months Ended | ​
​ | ​ | June 30 | ​ | June 30 | ​
(millions) |  | 2024 | ​ | ​ | 2023 | ​ | 2024 | ​ | ​ | 2023 | ​
Net Sales | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Global Industrial |  | ​ | $1,956.0 | ​ | ​ | ​ | $1,906.4 | ​ | ​ | $3,797.7 | ​ | ​ | ​ | $3,714.6 | ​
Global Institutional & Specialty | ​ | ​ | 1,372.7 | ​ | ​ | ​ | 1,273.7 | ​ | ​ | 2,643.0 | ​ | ​ | ​ | 2,404.9 | ​
Global Healthcare & Life Sciences | ​ | ​ | 395.0 | ​ | ​ | ​ | 395.3 | ​ | ​ | 777.9 | ​ | ​ | ​ | 781.4 | ​
Global Pest Elimination | ​ | ​ | 297.1 | ​ | ​ | ​ | 269.7 | ​ | ​ | 563.9 | ​ | ​ | ​ | 514.3 | ​
Corporate | ​ | ​ | - | ​ | ​ | ​ | 10.6 | ​ | ​ | - | ​ | ​ | ​ | 21.3 | ​
Subtotal at fixed currency rates | ​ | ​ | 4,020.8 | ​ | ​ | ​ | 3,855.7 | ​ | ​ | 7,782.5 | ​ | ​ | ​ | 7,436.5 | ​
Effect of foreign currency translation | ​ | ​ | (35.0) | ​ | ​ | ​ | (3.6) | ​ | ​ | (44.8) | ​ | ​ | ​ | (12.8) | ​
Consolidated reported GAAP net sales |  | ​ | $3,985.8 | ​ |  | ​ | $3,852.1 | ​ | ​ | $7,737.7 | ​ | ​ | ​ | $7,423.7 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating Income | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Global Industrial |  | ​ | $311.9 | ​ | ​ | ​ | $264.9 | ​ | ​ | $576.9 | ​ | ​ | ​ | $484.7 | ​
Global Institutional & Specialty | ​ | ​ | 320.7 | ​ | ​ | ​ | 213.4 | ​ | ​ | 568.7 | ​ | ​ | ​ | 343.5 | ​
Global Healthcare & Life Sciences | ​ | ​ | 33.7 | ​ | ​ | ​ | 33.2 | ​ | ​ | 70.7 | ​ | ​ | ​ | 68.6 | ​
Global Pest Elimination | ​ | ​ | 62.2 | ​ | ​ | ​ | 52.4 | ​ | ​ | 111.0 | ​ | ​ | ​ | 96.9 | ​
Corporate | ​ | ​ | (62.8) | ​ | ​ | ​ | (79.3) | ​ | ​ | (142.6) | ​ | ​ | ​ | (156.7) | ​
Subtotal at fixed currency rates | ​ | ​ | 665.7 | ​ | ​ | ​ | 484.6 | ​ | ​ | 1,184.7 | ​ | ​ | ​ | 837.0 | ​
Effect of foreign currency translation | ​ | ​ | (8.8) | ​ | ​ | ​ | 0.1 | ​ | ​ | (9.9) | ​ | ​ | ​ | (0.7) | ​
Consolidated reported GAAP operating income |  | ​ | $656.9 | ​ |  | ​ | $484.7 | ​ | ​ | $1,174.8 | ​ | ​ | ​ | $836.3 | ​

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment, including disclosure of changes for comparability of reportable segments. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References No definition available. + Details
Name: | ecl_ScheduleOfSegmentReportingInformationBySegmentIncludingChangesForComparabilityOfReportableSegmentsTableTextBlock
Namespace Prefix: | ecl_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration